These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

339 related articles for article (PubMed ID: 27824120)

  • 61. Discovery of (E)-N-(4-((4-methylpiperazin-1-yl)methyl)-3-(trifluoromethyl)phenyl)-3-((3-(2-(pyridin-2-yl)vinyl)-1H-indazol-6-yl)thio)propanamide (CHMFL-ABL-121) as a highly potent ABL kinase inhibitor capable of overcoming a variety of ABL mutants including T315I for chronic myeloid leukemia.
    Liu X; Wang B; Chen C; Jiang Z; Hu C; Wu H; Zhang Y; Liu X; Wang W; Wang J; Hu Z; Wang A; Huang T; Liu Q; Wang W; Wang L; Wang W; Ren T; Li L; Xia R; Ge J; Liu Q; Liu J
    Eur J Med Chem; 2018 Dec; 160():61-81. PubMed ID: 30317026
    [TBL] [Abstract][Full Text] [Related]  

  • 62. Combined Abl inhibitor therapy for minimizing drug resistance in chronic myeloid leukemia: Src/Abl inhibitors are compatible with imatinib.
    O'Hare T; Walters DK; Stoffregen EP; Sherbenou DW; Heinrich MC; Deininger MW; Druker BJ
    Clin Cancer Res; 2005 Oct; 11(19 Pt 1):6987-93. PubMed ID: 16203792
    [TBL] [Abstract][Full Text] [Related]  

  • 63. Activity of the potent dual Abl/Src tyrosine kinase inhibitor FB2 against Bcr-Abl positive cell lines in vitro and in vivo.
    Yuan X; Zhang Y; Zhang H; Jin J; Li X; Liu H; Feng Z; Chen X
    Leuk Res; 2011 Feb; 35(2):237-42. PubMed ID: 20739063
    [TBL] [Abstract][Full Text] [Related]  

  • 64. CDK4/CDK6 inhibition as a novel strategy to suppress the growth and survival of BCR-ABL1
    Schneeweiss-Gleixner M; Byrgazov K; Stefanzl G; Berger D; Eisenwort G; Lucini CB; Herndlhofer S; Preuner S; Obrova K; Pusic P; Witzeneder N; Greiner G; Hoermann G; Sperr WR; Lion T; Deininger M; Valent P; Gleixner KV
    EBioMedicine; 2019 Dec; 50():111-121. PubMed ID: 31761618
    [TBL] [Abstract][Full Text] [Related]  

  • 65. PF-114, a potent and selective inhibitor of native and mutated BCR/ABL is active against Philadelphia chromosome-positive (Ph+) leukemias harboring the T315I mutation.
    Mian AA; Rafiei A; Haberbosch I; Zeifman A; Titov I; Stroylov V; Metodieva A; Stroganov O; Novikov F; Brill B; Chilov G; Hoelzer D; Ottmann OG; Ruthardt M
    Leukemia; 2015 May; 29(5):1104-14. PubMed ID: 25394714
    [TBL] [Abstract][Full Text] [Related]  

  • 66. Synergistic interactions between imatinib mesylate and the novel phosphoinositide-dependent kinase-1 inhibitor OSU-03012 in overcoming imatinib mesylate resistance.
    Tseng PH; Lin HP; Zhu J; Chen KF; Hade EM; Young DC; Byrd JC; Grever M; Johnson K; Druker BJ; Chen CS
    Blood; 2005 May; 105(10):4021-7. PubMed ID: 15665113
    [TBL] [Abstract][Full Text] [Related]  

  • 67. Imatinib resistance associated with BCR-ABL upregulation is dependent on HIF-1alpha-induced metabolic reprograming.
    Zhao F; Mancuso A; Bui TV; Tong X; Gruber JJ; Swider CR; Sanchez PV; Lum JJ; Sayed N; Melo JV; Perl AE; Carroll M; Tuttle SW; Thompson CB
    Oncogene; 2010 May; 29(20):2962-72. PubMed ID: 20228846
    [TBL] [Abstract][Full Text] [Related]  

  • 68. Induction of apoptosis in imatinib sensitive and resistant chronic myeloid leukemia cells by efficient disruption of bcr-abl oncogene with zinc finger nucleases.
    Huang N; Huang Z; Gao M; Luo Z; Zhou F; Liu L; Xiao Q; Wang X; Feng W
    J Exp Clin Cancer Res; 2018 Mar; 37(1):62. PubMed ID: 29554925
    [TBL] [Abstract][Full Text] [Related]  

  • 69. Dasatinib in imatinib-resistant Philadelphia chromosome-positive leukemias.
    Talpaz M; Shah NP; Kantarjian H; Donato N; Nicoll J; Paquette R; Cortes J; O'Brien S; Nicaise C; Bleickardt E; Blackwood-Chirchir MA; Iyer V; Chen TT; Huang F; Decillis AP; Sawyers CL
    N Engl J Med; 2006 Jun; 354(24):2531-41. PubMed ID: 16775234
    [TBL] [Abstract][Full Text] [Related]  

  • 70. A sequential blockade strategy for the design of combination therapies to overcome oncogene addiction in chronic myelogenous leukemia.
    Chen R; Gandhi V; Plunkett W
    Cancer Res; 2006 Nov; 66(22):10959-66. PubMed ID: 17108134
    [TBL] [Abstract][Full Text] [Related]  

  • 71. A molecular and biophysical comparison of macromolecular changes in imatinib-sensitive and imatinib-resistant K562 cells exposed to ponatinib.
    Yandim MK; Ceylan C; Elmas E; Baran Y
    Tumour Biol; 2016 Feb; 37(2):2365-78. PubMed ID: 26373734
    [TBL] [Abstract][Full Text] [Related]  

  • 72. Histone deacetylase inhibitor LAQ824 both lowers expression and promotes proteasomal degradation of Bcr-Abl and induces apoptosis of imatinib mesylate-sensitive or -refractory chronic myelogenous leukemia-blast crisis cells.
    Nimmanapalli R; Fuino L; Bali P; Gasparetto M; Glozak M; Tao J; Moscinski L; Smith C; Wu J; Jove R; Atadja P; Bhalla K
    Cancer Res; 2003 Aug; 63(16):5126-35. PubMed ID: 12941844
    [TBL] [Abstract][Full Text] [Related]  

  • 73. Abl tyrosine kinase inhibitors for overriding Bcr-Abl/T315I: from the second to third generation.
    Tanaka R; Kimura S
    Expert Rev Anticancer Ther; 2008 Sep; 8(9):1387-98. PubMed ID: 18759691
    [TBL] [Abstract][Full Text] [Related]  

  • 74. Sorafenib induces apoptosis specifically in cells expressing BCR/ABL by inhibiting its kinase activity to activate the intrinsic mitochondrial pathway.
    Kurosu T; Ohki M; Wu N; Kagechika H; Miura O
    Cancer Res; 2009 May; 69(9):3927-36. PubMed ID: 19366808
    [TBL] [Abstract][Full Text] [Related]  

  • 75. Imatinib mesylate induces cisplatin hypersensitivity in Bcr-Abl+ cells by differential modulation of p53 transcriptional and proapoptotic activity.
    Skorta I; Oren M; Markwardt C; Gutekunst M; Aulitzky WE; van der Kuip H
    Cancer Res; 2009 Dec; 69(24):9337-45. PubMed ID: 19934315
    [TBL] [Abstract][Full Text] [Related]  

  • 76. Small interfering RNA against BCR-ABL transcripts sensitize mutated T315I cells to nilotinib.
    Koldehoff M; Kordelas L; Beelen DW; Elmaagacli AH
    Haematologica; 2010 Mar; 95(3):388-97. PubMed ID: 20207846
    [TBL] [Abstract][Full Text] [Related]  

  • 77. The novel Aurora A kinase inhibitor MLN8237 is active in resistant chronic myeloid leukaemia and significantly increases the efficacy of nilotinib.
    Kelly KR; Ecsedy J; Medina E; Mahalingam D; Padmanabhan S; Nawrocki ST; Giles FJ; Carew JS
    J Cell Mol Med; 2011 Oct; 15(10):2057-70. PubMed ID: 21091633
    [TBL] [Abstract][Full Text] [Related]  

  • 78. Discovery of 3-((3-amino-
    El-Damasy AK; Kim HJ; Park JW; Nam Y; Hur W; Bang EK; Keum G
    J Enzyme Inhib Med Chem; 2023 Dec; 38(1):2228515. PubMed ID: 37470410
    [TBL] [Abstract][Full Text] [Related]  

  • 79. Cyclin-dependent kinase 7/9 inhibitor SNS-032 abrogates FIP1-like-1 platelet-derived growth factor receptor α and bcr-abl oncogene addiction in malignant hematologic cells.
    Wu Y; Chen C; Sun X; Shi X; Jin B; Ding K; Yeung SC; Pan J
    Clin Cancer Res; 2012 Apr; 18(7):1966-78. PubMed ID: 22447844
    [TBL] [Abstract][Full Text] [Related]  

  • 80. Piperlongumine overcomes imatinib resistance by inducing proteasome inhibition in chronic myelogenous leukemia cells.
    Lan X; Hu M; Jiang L; Wang J; Meng Y; Chen X; Liu A; Ding W; Zhang H; Zhou H; Liu B; Peng G; Liao S; Chen X; Liu J; Shi X
    J Ethnopharmacol; 2023 Jan; 301():115815. PubMed ID: 36220508
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 17.